Citations

Clear

4610 citation(s) found for "Lu, Brian".

In vivo detectability of tau‐PET tracers in Alzheimer’s disease
Tissot, Cécile , Rahmouni, Nesrine, Tsai, Hsin‐Yeh, Therriault, Joseph, Macedo, Arthur C. , Servaes, Stijn, Stevenson, Jenna , Ziontz, Jacob , Liu, Peiwei, Gordon, Brian A., Pascual, Belén , Lowe, Val J. , Soleimani‐Meigooni, David, Oh, Hwamee , Klunk, William E, Jagust, William J., Baker, Suzanne L. , Pascual, Belen , Tissot, Cécile , Rahmouni, Nesrine , Therriault, Joseph , Servaes, Stijn , Lussier, Firoza Zubeida , Trudel, Lydia , Gordon, Brian A. , Soleimani‐Meigooni, David N. , Klunk, William E. , Rosa-Neto, Pedro , Jagust, William J. , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109804 Get It

Abstract Background Tau‐PET tracers are essential for visualizing pathology in Alzheimer’s (AD). High detectability to tau is crucial for early detection and monitoring of tau deposition. This study compares the noise to dynamic range ratio (NRR) of [ 18 F]FTP, [ 18 F]MK6240, [ 18 F]PI2620, and [ 18 F]RO948, cross‐sectionally and longitudinally. Methods 460 individuals from the HEAD study (23 cognitively unimpaired (CU) young, 249 CU old and 188 cognitively impaired) underwent [ 18 F]FTP and [ 18 F]MK6240 tau‐PET scans; 94 additionally received [ 18 F]PI2620 and [ 18 F]RO948. A subset of 28 individuals (15 CU and 13 CI) underwent [ 18 F]FTP and [ 18 F]MK6240 follow‐up scans (1.5 ± 0.1 years later). Annual change was measured as [(followup‐baseline)/time between scans]. Noise was calculated as the standard deviation (SD) of CU Aβ‐ participants aged ≤65 (SD CUAβ‐≤65 ). The dynamic range was calculated as the SD across all subjects (SD range ). A lower the NRR (=SD CUAβ‐≤65 /SD range ) indicates more detectability. Analyses were performed at both region‐of‐interest and voxel‐wise levels. Results Across the whole cohort, [ 18 F]MK6240 exhibited lower NRR than [ 18 F]FTP in all regions. Voxel‐wise, differences were most pronounced in the frontal medial temporal regions (Figure 1). Within the four‐tracers subset, [ 18 F]PI2620 and [ 18 F]FTP showed the highest NRR in Braak II, followed by [ 18 F]RO948 and [ 18 F]MK6240. In Braak IV‐VI, [ 18 F]MK6240 consistently demonstrated the lowest values, followed by [ 18 F]PI2620, [ 18 F]FTP and [ 18 F]RO948. Similarly, in metatemporal‐ROI and Braak III, [ 18 F]MK6240 remained the lowest, however followed by [ 18 F]FTP, [ 18 F]PI2620 and [ 18 F]RO948 (Figure 2). Lower [ 18 F]MK6240 NRR was due to larger SD range , while [ 18 F]FTP's lower values stemmed from smaller SD CUAβ‐≤65 . Conversely, high [ 18 F]PI2620 and [ 18 F]RO948 values are driven by larger SD CUAβ‐≤65 . Longitudinal analyses further confirmed that [ 18 F]MK6240 exhibited the lowest NRR across the entire brain, including AD‐related regions, with voxel‐wise differences mainly in the temporal and parietal lobes. Conclusion Tau‐PET tracers exhibit significant variability in detectability. [ 18 F]MK6240 consistently demonstrated lower NRR, implying better detectability across all regions, cross‐sectionally and longitudinally. Despite differences in NRR, [ 18 F]FTP, [ 18 F]RO948 and [ 18 F]PI2620 followed similar pattern. These results provide insights into the differential tracer detectability, helping guide their optimal use in detecting and tracking tau pathology. Ongoing follow‐up scans will further clarify longitudinal tracer detectability and its implications for tau progression in AD.
Longitudinal progression and harmonization of tau‐PET tracers
Ferreira, Pamela C.L., Povala, Guilherme, Amaral, Lívia , Tudorascu, Dana , Finn, Quentin, Rahmouni, Nesrine, Therriault, Joseph, Servaes, Stijn, Stevenson, Jenna , Macedo, Arthur C. , Masdeu, Joseph C. , Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee , Pascual, Belén , Gordon, Brian A., Baker, Suzanne L. , Pascual, Belen , Bauer‐Negrini, Guilherme , Ferreira, Pâmela C.L. , Povala, Guilherme , Bellaver, Bruna , Lussier, Firoza Zubeida , Rahmouni, Nesrine , Therriault, Joseph , Servaes, Stijn , Masdeu, Joseph C , Soleimani‐Meigooni, David N. , Fortea, Juan , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109744 Get It

Abstract Background Tau‐PET tracers have been used to monitor the progression of Alzheimer’s disease (AD). However, different tracers present distinct patterns of binding throughout the brain, challenging the harmonization of their findings. Leveraging the HEAD Study, the largest head‐to‐head study of tau‐PET tracers, we recently developed the Uniτ scale, which cross‐sectionally harmonizes Flortaucipir and MK6240 onto a universal tau‐PET measurement. Here, we provide a preliminary evaluation of the Uniτ scale’s longitudinal performance in HEAD and two independent cohorts. Methods We assessed 422 individuals across the AD spectrum with longitudinal tau‐PET from three cohorts: HEAD [13 cognitively unimpaired (CU), 9 cognitively impaired (CI) individuals, scanned head‐to‐head with Flortaucipir and MK6240], ADNI [74 CU, 208 CI, tracer: Flortaucipir], and TRIAD [72 CU, 46 CI, tracer: MK6240]. Standardized uptake ratios (SUVRs) were harmonized to Uniτ using the Uniτ Ecosystem ( unitau.app ). Braak I‐II and the Meta‐Temporal regions were used as regions of interest. Annual tau‐PET uptake change was calculated, and the effect size was defined as the mean annual change divided by its standard deviation. Results In HEAD, annual change in tau‐PET uptake in Braak I‐II across CU and CI was only detectable in MK6240 (Figure 1A). However, both tracers detected significant annual changes in the Meta‐Temporal ROI for CI (Figure 1B). In both ADNI (Flortaucipir) and TRIAD (MK6240), changes in tau‐PET uptake in Braak I‐II regions were not significant (Figures 2‐3A). However, across all cohorts, the Meta‐Temporal ROI consistently showed detectable annual tau‐PET increases—most pronounced among CI—leading to larger effect sizes than in Braak I‐II (Figures 1‐3B). The Uniτ harmonization did not fundamentally alter the pattern of the findings. However, in ADNI (Flortaucipir), Uniτ yielded a slightly higher effect size than SUVR in CU for both Braak I‐II and Meta‐Temporal regions. Conclusion In this large longitudinal sample, our findings confirm that Flortaucipir and MK6240 can detect tau PET changes over time likely associated with the progression of tau tangle pathology. While MK6240 appears to show greater progression in CU, both tracers progress similarly in CI. Our data also suggested that Uniτ harmonized tau PET measurements maintain the longitudinal characteristics of each tau PET tracer for use in clinical trials.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, C. R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Q., Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew , Whittington, Alex , Carrillo, Maria, Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, H., Stephenson, Diane , Tatton, Nadine , Brendel, M., Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald, Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Kolb, Hartmuth C. , Brendel, Matthias , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109722 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [¹⁸F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [¹⁸F]flortaucipir (ADNI), [¹⁸F]MK‐6240 (CPAS), and [¹⁸F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([¹⁸F]flortaucipir) and AIBL ([¹⁸F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [¹⁸F]flortaucipir and [¹⁸F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([¹⁸F]PI‐2620) are underway.
Vestibular and Audiometric Outcomes in Cochlear Implantation With Simultaneous Endolymphatic Sac Decompression for Patients With Ménière Disease
Khandalavala, Karl R. , Babajanian, Eric E. , Marinelli, John P. , Lohse, Christine M. , Driscoll, C W, Carlson, Matthew L., Neff, Brian A., Dornhoffer, James R. , Olson, Brennan G, Driscoll, Colin L., Olson, Brennan , Driscoll, Colin L. W., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | December 23, 2025 | Volume: 47 | Issue: 3 | Pages: 475-478

10.1097/mao.0000000000004788 | PMID 41432410 Get It

Objective: To evaluate the impact of cochlear implantation (CI) and simultaneous endolymphatic sac decompression (ELSD) on vestibular and audiometric outcomes in patients with advanced Ménière disease (MD). Study design: Historical cohort. Setting: Tertiary academic medical center. Patients: Patients with medically refractory MD who underwent CI with or without simultaneous ELSD from 2000 through 2024. Interventions: CI with or without ELSD. Main outcome measures: Post-CI patient-reported changes in vertigo severity and frequency, Consonant-Nucleus-Consonant word (CNCw) scores, and AzBio sentences in quiet scores. Results: Ninety-nine patients with preoperative vertigo secondary to MD were eligible for study, including 17 (17%) who underwent simultaneous ELSD. In total, 15 (88%) and 2 (12%) of the 17 patients with simultaneous ELSD reported improvement and stability in vertigo severity, respectively; in comparison, 26 (32%), 40 (49%), and 16 (20%) of the 82 patients with CI alone reported improvement, stability, and worsening in vertigo severity, respectively ( P <0.001). Likewise, 15 (88%) and 2 (12%) of the patients with simultaneous ELSD reported improvement and stability in vertigo frequency, respectively, whereas 21 (26%), 43 (52%), and 18 (22%) of patients with CI alone reported improvement, stability, and worsening in vertigo frequency, respectively ( P <0.001). Post-CI speech recognition scores were not significantly different between the simultaneous ELSD and CI alone groups [median (IQR) CNCw 70 (38 to 82) vs. 72 (58 to 82) and median (IQR) AzBio quiet 87 (67 to 96) vs. 87 (73 to 94), respectively]. Conclusions: In patients with MD, CI with simultaneous ELSD provides improvement in vertigo symptoms and similar audiometric outcomes when compared with CI alone. In appropriately selected patients with both refractory vestibular symptoms and sensorineural hearing loss meeting criteria for implantation, CI with simultaneous ELSD offers improvement in severity and frequency of vertigo as well as successful auditory rehabilitation.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Assessing the Current Stage of Burnout in Hematology-Oncology Faculty and Trainees— Is There a Path to Remission?
Liddell, S. , Hendrickson, Andrea E. Wahner , Costello, Brian A. , Price, Katharine A. , Ruddy, Kathryn J. , Marshall, Ariela L. , O’Sullivan, Ciara C. , Liddell, Savannah S , O'Sullivan, Ciara C, Marshall, Ariela , Tevaarwerk, Amyé , Siontis, Brittany L. , Gergelis, Kimberly R. , West, Colin P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.7087 | PMID 41671452 Get It

Physician burnout is prevalent and contributes to the high number of physicians choosing to leave clinical practice. The field of hematology-oncology (HO) poses unique challenges for trainees and staff physicians who have to deliver bad news, manage complicated psychosocial situations, deal with the limited ability to prolong life, and juggle multiple time-sensitive demands from coworkers, patients, and families. Furthermore, they often face the death of their patients, along with its emotional toll on patients’ families and the physicians themselves. Burnout in HO is prevalent and increasing, with many physicians reporting in several studies that they plan to reduce working hours and/or retire early. The demand for hematologists and oncologists is rapidly rising, but in the setting of a worsening HO workforce shortage and an increasing number of patients with cancer. Therefore, it is imperative to develop strategies to mitigate or address burnout in HO physicians to improve well-being and prevent attrition. Herein, we describe risk factors and causes of physician burnout in HO trainees and practicing physicians in the United States, with a focus on institutional and individual strategies to address this issue. We also provide recommendations to address the burnout epidemic from the HO standpoint.
Reduction of Erroneous ST-segment Elevation Myocardial Infarction Diagnoses
Klassen, Aaron B. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Connelly, Rebecca A., Konz, Brent A, Bartelt, Jennifer M., Ring, Michael T, Winkel, Daniel, Churchill, Jason T, Griffin, Dawn M., Brady, Brian J., Bartelt, J., Johnson, Matthew P. , Gulati, Rajiv , Bennett, Courtney , Barsness, Gregory W. , Bartelt, Jason D, Wiley, Brandon, Porter, John L. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Fatema, Kaniz , Connelly, Rebecca A., Winkel, Daniel B., Griffin, Dawn M., Brady, Brian J., Bartelt, Jason D., Wiley, Brandon M.

Mayo Clinic

CIN: Computers, Informatics, Nursing | December 17, 2025 | Volume: 44 | Issue: 2 | Pages: No page available

10.1097/cin.0000000000001379 | PMID 41371987 Get It

An ST-segment elevation myocardial infarction is a life-threatening condition within the spectrum of acute coronary syndrome, with well-recognized implications for short-term and long-term health outcomes. Retrospective review of our institutional electronic health records identified patterns of inaccurate acute coronary syndrome diagnostic assignment, including the presence of erroneous ST-segment elevation myocardial infarction diagnoses in discharge records. Such erroneous diagnoses in the durable health record may increase risk to patients through inadequate risk assessment and inappropriate follow-up care. Misapplication of a shortcut in our electronic health record system for rapidly ordering emergent cases was identified as a potential cause of the quality gap. To address this issue, a nurse-led quality improvement project was developed by using the define, measure, analyze, improve, and control framework. The project intervention decreased the percentage of patients with erroneous diagnoses from 24% to 7% and marginally improved nursing staff satisfaction. Our project successfully addressed an institutional quality concern. Our goal of reducing erroneous discharge diagnoses with minimal disruption to our existing practice was achieved, positively affecting our patients. Including both nurse leaders and frontline health care workers ensured the success of our project.
Effect of Previous Embolization on Radiation-Induced Changes After Stereotactic Radiosurgery for Brain Arteriovenous Malformations
Mokua, Collins , Ramirez-Garcia, Kristina , Nguyen, Justin H. , Lee, Cheng‐Chia , Ding, Dale , Woo, Shiao Y. , Kondziolka, Douglas, Feliciano, Caleb , Rodriguez-Mercado, R, Cockroft, Kevin M. , Simon, Scott D. , Lee, John Y. K., Sheehan, Jason P. , Chen, Ching-Jen , Ding, Dale , Becerril‐Gaitan, Andrea , Nguyen, Justin, Cifarelli, Christopher P. , Liščák, Roman , Williams, Brian J. , Yusuf, Mehran Behruj , Warnick, Ronald E. , Trifiletti, Daniel M. , Mathieu, David , Chen, Ching‐Jen

Mayo Clinic

Neurosurgery | December 16, 2025 | Volume: 99 | Issue: 3 | Pages: 593-602

10.1227/neu.0000000000003880 | PMID 41400380 Get It

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) for brain arteriovenous malformations (AVMs) can cause radiation-induced changes (RIC), but its interactions with AVM embolization are not well established. The aim of this study was to assess the effect of previous embolization on RIC in SRS-treated AVM patients. METHODS: Data of AVM patients treated with single-session SRS from 1987 to 2018 were retrieved from the International Radiosurgery Research Foundation. Univariable and stepwise backward logistic regression models were used to identify RIC predictors. Patients were stratified into those who received pre-SRS embolization (E + SRS) vs those who did not (SRS-only). Radiologic RIC (rRIC) was the primary end point. Secondary outcomes included symptomatic RIC (sRIC) and permanent symptomatic RIC (pRIC). RESULTS: Among 1187 AVM patients, the mean age was 36.4 years (SD 16.8), with 50.4% female patients. AVMs had a mean untreated AVM volume of 5.2 cm 3 . A total of 130 patients (11%) underwent neoadjuvant embolization (E + SRS). The overall rRIC and sRIC rates were 32.8% and 12.1%, respectively, with time to rRIC and sRIC being significantly longer in the E + SRS vs SRS-only cohorts (103.6 ± 339.4 vs 11.3 ± 12.5 and 60.4 ± 262.9 vs 9.5 ± 9.0 months, respectively). Seizures at presentation and ≥3-cm untreated AVM volume significantly correlated with a higher likelihood of rRIC (adjusted odds ratio [aOR] 2.32 [1.25-4.30] and aOR 2.77 [1.24-6.16], respectively). Age and pre-SRS embolization were associated with a significantly lower risk of rRIC (aOR 0.97 [0.96-0.99] and aOR 0.32 [0.13-0.74], respectively). The E + SRS cohort had significantly reduced odds of rRIC (aOR = 0.37 [0.15-0.89]) and pRIC (aOR = 0.04 [0.00-0.30]) after adjusting for significant covariates. CONCLUSION: Seizures at presentation and larger untreated AVM volume were independently associated with an increased risk of rRIC, whereas older age and pre-SRS embolization were protective. Notably, patients who underwent embolization before SRS had lower odds of rRIC and pRIC, with delayed onset of complications compared with SRS-only.
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Gore, John L. , Wolff, Erika M. , Nash, Michael G. , Comstock, Bryan A. , Gilbert, Scott M. , Chang, Sam S., Chisolm, Stephanie , MacLean, Douglas B., Wright, Jonathan L. , Kates, Max , Pohar, Kamal S. , Guzzo, Thomas J., Bivalacqua, Trinity J, Nepple, Kenneth G. , Montgomery, Jeffrey S., Scarpato, Kristen R., Master, Viraj A. , Chen, David YT , Mossanen, Matthew , O’Neil, Brock , Tyson, Mark D. , Mansour, Ahmed M. , Chamie, Karim, Riggs, Stephen B. , Kukreja, Janet Baack , Peyton, Cheri L. , Nix, Jeffrey W. , Dickstein, Rian, Sankin, Alex , Lane, Brian R. , Bassett, Jeffrey C. , Patel, Sanjay , Lee, Eugene K. , Ritch, Chad R. , Follmer, Kristin , Kim, Sung Min , Kessler, Larry G. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J., Catto, James W.F. , Sankin, Alexander , Woldu, Solomon L , Master, Viraj A , Chen, David Y T , Daneshmand, Siamak , O'Neil, Brock B , Westerman, Mary E , Kamat, Ashish M. , Modi, Parth K , Peyton, Charles C , Gadzinski, Adam J , Shore, Neal , Patel, Sanjay , Ritch, Chad R , Follmer, Kristin M , Kim, Sung Min , Kessler, Larry G , Bivalacqua, Trinity J. , Daneshmand, Siamak , Westerman, Mary E. , Garg, Tullika K. , Shore, Neal D. , Morris, David S. , Macleod, Liam Connor , Lee, Jenney R. , Smith, Angela B. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2025 | Volume: 44 | Issue: 4 | Pages: 274-285

10.1200/jco-25-01324 | PMID 41397208 Get It

PURPOSE To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Slomovitz, Brian M. , Weroha, S. John , Chon, Hye Sook, Podder, Vivek , Markham, Merry Jennifer , Backes, Floor , Thomas, Eric D. , Tenney, Meaghan , Miller, David S. , Muller, Carolyn Y., Callahan, Michael J. , Liu, J. Rebecca, Teplinsky, Eleonora , Kamat, Aparna A., Chern, Jing‐Yi , Murphy, Martina, Choong, Grace M. , Moore, Elena Diaz, Alvarez, Edwin , Rodgers, William H. , Copeland, Larry J. , Herzog, Thomas J. , Podder, Vivek , Markham, Merry J , Backes, Floor , Tenney, Meaghan Elizabeth , Westin, Shannon N , Miller, David S , Edelson, Mitchell I , Teplinsky, Eleonora , Guy, Michael , Choong, Grace M , O'Malley, David M , Copeland, Larry J , Herzog, Thomas J , Coleman, Robert , Gershenson, David M , Deng, Wei, Chen, Lee-may , Edelson, Mitchell I. , Holman, Laura L. , Lea, Jayanthi Sivasothy , O’Malley, David M. , Coleman, Robert L. , Gershenson, David M.

Mayo Clinic

Journal of Clinical Oncology | December 12, 2025 | Volume: 44 | Issue: 3 | Pages: 153-163

10.1200/jco-25-01348 | PMID 41385758 Get It

PURPOSE Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.